CCM
TCRX icon

CAAS Capital Management’s TScan Therapeutics TCRX Stock Holding History

CAAS Capital Management’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-25,633
Closed -$115K – 916
2021
Q4 		$115K Sell
25,633
-49,367
-66% -$356K ﹤0.01% 708
2021
Q3 		$626K Buy
+75,000
New +$696K 0.01% 577

Other funds holding TCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

CAAS Capital Management's TCRX Position: Q1 2022 in Review

CAAS Capital Management sold out of TScan Therapeutics (TCRX) in Q1 2022, closing a stake of 25,633 shares — an estimated $115K sold.

CAAS Capital Management first reported a position in TCRX in Q3 2021 and held it in 2 quarters. The position peaked at $626K in Q3 2021. 25 funds tracked by Wall St. Rank hold TCRX as of Q1 2022.

  • CAAS Capital Management reported no remaining TScan Therapeutics position as of Q1 2022 after selling out during the quarter.
  • CAAS Capital Management sold 25,633 TScan Therapeutics shares in Q1 2022, an estimated $115K.
  • CAAS Capital Management first reported a position in TScan Therapeutics in Q3 2021 and held it in 2 quarters.
  • CAAS Capital Management's TScan Therapeutics position peaked at $626K in Q3 2021.
  • 25 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2022.

Based on CAAS Capital Management's 13F filing for Q1 2022, filed 13 May 2022.